Significantly, by downregulating the pro-apoptotic protein Bax and upregulating the anti-apoptotic protein Bcl-2, the combination treatment altered apoptotic signaling and may have a protective impact against hepatocyte death, a crucial mechanism in the development of NAFLD. This evidence concerns the gene BCL2 and metabolic dysfunction-associated steatotic liver disease.